Hemp & Health SA
NNEWCONNECT:HMP3.65
PLN
-0.13
(-3.44%)
Hemp & Health SA
NEWCONNECT:HMP
(NewConnect)
Recent
price
3.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Hemp & Health S.A. is a Poland-based healthcare and life sciences company engaged in the development, commercialization, distribution, and wholesale of hemp-derived consumer health products, wellness supplements, and pharmaceutical-grade medical cannabis. Founded in 2005 and headquartered in Katowice, Poland, the company serves individual consumers, retail pharmacy networks, clinical healthcare practitioners, and specialty wellness retailers across Poland and the broader Central European region. The company operates through two core business segments: Medical Cannabis & Pharmaceuticals and Hemp Health & Wellness Products. Its comprehensive product and service portfolio comprises: prescription-grade medical cannabis flos, standardized cannabinoid extracts, and active pharmaceutical ingredients (APIs) distributed to licensed pharmacies; cannabidiol (CBD) wellness formulations, including full-spectrum and broad-spectrum sublingual oils, water-soluble drops, concentrated tinctures, and oral dietary capsules; therapeutic and dermatological cosmetics, such as regenerating facial creams, soothing muscle balms, moisturizing lotions, and protective skin ointments formulated with hemp extracts and cold-pressed hemp seed oil; specialty hemp foods, seed-based nutritional goods, and herbal tea infusions; specialized wholesale supply and white-label formulation services for third-party commercial brands; and legacy telemedical consultation and remote health diagnostic support infrastructure. In recent developments, Hemp & Health S.A. has completed a strategic transformation shifting its principal operational focus toward high-margin medical cannabis importation, registration, and distribution across Central European pharmacy chains. The company has secured key commercial partnerships and supply agreements with European cultivators and Good Manufacturing Practice (GMP)-certified pharmaceutical processors to broaden its catalog of registered medical marijuana strains. Additionally, the company has expanded its pharmacy distribution reach, launched new therapeutic-grade CBD product lines, optimized its supply chain and white-label manufacturing capabilities, and undertaken operational restructuring to accelerate market penetration within regulated European cannabinoid markets.